Pulmonary arterial hypertension and congenital heart disease: Targeted therapies and operability

Journal of Thoracic and Cardiovascular Surgery

Volumn 138, Issue 3, 2009, Pages 785-786

  Beghetti, Maurice ^a   Tissot, Cecile ^a  

^a GENEVA UNIVERSITY HOSPITALS   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

BOSENTAN;

CONGENITAL HEART DISEASE; DISEASE ASSOCIATION; DISEASE SEVERITY; HEART ATRIUM PRESSURE; HUMAN; LETTER; PRIORITY JOURNAL; PULMONARY HYPERTENSION; SYSTEMIC CIRCULATION; SYSTEMIC VASCULAR RESISTANCE;

AGED; ANTIHYPERTENSIVE AGENTS; CHILD; FEMALE; FOLLOW-UP STUDIES; HEART DEFECTS, CONGENITAL; HEMODYNAMICS; HUMANS; HYPERTENSION, PULMONARY; RECURRENCE; SULFONAMIDES;

EID: 68749104539     PISSN: 00225223     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jtcvs.2009.04.034     Document Type: Letter

References (5)

1. Hoetzenecker K., Ankersmit H.J., Bonderman D., et al. Atrial septal defect repair after a 10-month treatment with bosentan in a patient with severe pulmonary arterial hypertension: a case report. J Thorac Cardiovasc Surg 137 (2009) 760-761
2. Dimopoulos K., Peset A., and Gatzoulis M.A. Evaluating operability in adults with congenital heart disease and the role of pretreatment with targeted pulmonary arterial hypertension therapy. Int J Cardiol 129 (2008) 163-171
3. Berner M., Beghetti M., Spahr-Schopfer I., Oberhansli I., and Friedli B. Inhaled nitric oxide to test the vasodilator capacity of the pulmonary vascular bed in children with long-standing pulmonary hypertension and congenital heart disease. Am J Cardiol 77 (1996) 532-535
4. Balzer D.T., Kort H.W., Day R.W., et al. Inhaled Nitric Oxide as a Preoperative Test (INOP Test I): the INOP Test Study Group. Circulation 106 12 suppl. 1 (2002) I76-I81
5. Haworth S.G., and Hislop A.A. Treatment and survival in children with pulmonary arterial hypertension: the UK Pulmonary Hypertension Service for Children 2001-2006. Heart 95 (2009) 312-317